References
- Campochiaro C, Tomelleri A, Cavalli G, Berti A, Dagna L. Erdheim–Chester disease. Eur J Intern Med 2015; 26(4):223-9; PMID:25865950; https://doi.org/https://doi.org/10.1016/j.ejim.2015.03.004
- Emile JF, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J, Requena-Caballero L, Jordan MB, Abdel-Wahab O, Allen CE et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 2016; 127(22):2672-81; PMID:26966089; https://doi.org/https://doi.org/10.1182/blood-2016-01-690636
- Cavalli G, Guglielmi B, Berti A, Campochiaro C, Sabbadini MG, Dagna L. The multifaceted clinical presentations and manifestations of Erdheim–Chester disease: comprehensive review of the literature and of 10 new cases. Ann Rheum Dis 2013; 72(10):1691-5; PMID:23396641; https://doi.org/https://doi.org/10.1136/annrheumdis-2012-202542
- Arnaud L, Hervier B, Neel A, Hamidou MA, Kahn JE, Wechsler B, Pérez-Pastor G, Blomberg B, Fuzibet JG, Dubourguet F et al. CNS involvement and treatment with interferon-alpha are independent prognostic factors in Erdheim–Chester disease: a multicenter survival analysis of 53 patients. Blood 2011; 117(10):2778-82; PMID:21239701; https://doi.org/https://doi.org/10.1182/blood-2010-06-294108
- Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127(20):2375-90; PMID:26980727; https://doi.org/https://doi.org/10.1182/blood-2016-01-643569
- Haroche J, Amoura Z, Trad SG, Wechsler B, Cluzel P, Grenier PA, Piette JC. Variability in the efficacy of interferon-alpha in Erdheim–Chester disease by patient and site of involvement: results in eight patients. Arthritis Rheum 2006; 54(10):3330-6; PMID:17009306; https://doi.org/https://doi.org/10.1002/art.22165
- Diamond EL, Dagna L, Hyman DM, Cavalli G, Janku F, Estrada-Veras J, Ferrarini M, Abdel-Wahab O, Heaney ML, Scheel PJ et al. Consensus guidelines for the diagnosis and clinical management of Erdheim–Chester disease. Blood 2014; 124(4):483-92; PMID:24850756; https://doi.org/https://doi.org/10.1182/blood-2014-03-561381
- Diamond EL, Durham BH, Haroche J, Yao Z, Ma J, Parikh SA, Wang Z, Choi J, Kim E, Cohen-Aubart F et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov 2016; 6(2):154-65; PMID:26566875; https://doi.org/https://doi.org/10.1158/2159-8290.CD-15-0913
- Haroche J, Charlotte F, Arnaud L, von Deimling A, Helias-Rodzewicz Z, Hervier B, Cohen-Aubart F, Launay D, Lesot A, Mokhtari K et al. High prevalence of BRAF V600E mutations in Erdheim–Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012; 120(13):2700-3; PMID:22879539; https://doi.org/https://doi.org/10.1182/blood-2012-05-430140
- Cangi MG, Biavasco R, Cavalli G, Grassini G, Dal-Cin E, Campochiaro C, Guglielmi B, Berti A, Lampasona V, von Deimling A et al. BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim–Chester disease. Ann Rheum Dis 2015; 74(8):1596-602; PMID:24671772; https://doi.org/https://doi.org/10.1136/annrheumdis-2013-204924
- Cavalli G, De Luca G, Dagna L. Advances in potential targeted therapies for Erdheim–Chester disease. Expert Opin Orphan Drugs 2017; 5(3):253-60.
- Welsh SJ, Corrie PG. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol 2015; 7(2):122-36; PMID:25755684; https://doi.org/https://doi.org/10.1177/1758834014566428
- Stoppacciaro A, Ferrarini M, Salmaggi C, Colarossi C, Praderio L, Tresoldi M, Beretta AA, Sabbadini MG. Immunohistochemical evidence of a cytokine and chemokine network in three patients with Erdheim–Chester disease: implications for pathogenesis. Arthritis Rheum 2006; 54(12):4018-22; PMID:17133532; https://doi.org/https://doi.org/10.1002/art.22280
- Arnaud L, Gorochov G, Charlotte F, Lvovschi V, Parizot C, Larsen M, Ghillani-Dalbin P, Hervier B, Kahn JE, Deback C et al. Systemic perturbation of cytokine and chemokine networks in Erdheim–Chester disease: a single-center series of 37 patients. Blood 2011; 117(10):2783-90; PMID:21205927; https://doi.org/https://doi.org/10.1182/blood-2010-10-313510
- Mossetti G, Rendina D, Numis FG, Somma P, Postiglione L, Nunziata V. Biochemical markers of bone turnover, serum levels of interleukin-6/interleukin-6 soluble receptor and bisphosphonate treatment in Erdheim–Chester disease. Clin Exp Rheumatol 2003; 21(2):232-6; PMID:12747282
- Haroche J, Cohen-Aubart F, Emile JF, Maksud P, Drier A, Toledano D, Barete S, Charlotte F, Cluzel P, Donadieu J et al. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim–Chester disease. J Clin Oncol 2015; 33(5):411-8; PMID:25422482; https://doi.org/https://doi.org/10.1200/JCO.2014.57.1950
- Dagna L, Corti A, Langheim S, Guglielmi B, De Cobelli F, Doglioni C, Fragasso G, Sabbadini MG, Ferrarini M. Tumor necrosis factor alpha as a master regulator of inflammation in Erdheim–Chester disease: rationale for the treatment of patients with infliximab. J Clin Oncol 2012; 30(28):e286-90; PMID:22869874; https://doi.org/https://doi.org/10.1200/JCO.2012.41.9911
- Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008; 112(10):3959-64; PMID:18784373; https://doi.org/https://doi.org/10.1182/blood-2008-05-155846
- Berti A, Ferrarini M, Ferrero E, Dagna L. Cardiovascular manifestations of Erdheim–Chester disease. Clin Exp Rheumatol 2015; 33(2 Suppl 89):S-155-63; PMID:25738753
- Pardridge WM. Blood–brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody. Expert Opin Drug Deliv 2015; 12(2):207-22; PMID:25138991; https://doi.org/https://doi.org/10.1517/17425247.2014.952627
- Cavalli G, Biavasco R, Borgiani B, Dagna L. Oncogene-induced senescence as a new mechanism of disease: the paradigm of Erdheim–Chester disease. Front Immunol 2014; 5:281; PMID:24982657; https://doi.org/https://doi.org/10.3389/fimmu.2014.00281
- Kuilman T, Michaloglou C, Vredeveld LC, Douma S, van Doorn R, Desmet CJ, Aarden LA, Mooi WJ, Peeper DS. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008; 133(6):1019-31; PMID:18555778; https://doi.org/https://doi.org/10.1016/j.cell.2008.03.039
- Cavalli G, Dinarello CA. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology (Oxford) 2015; 54(12):2134-44; PMID:26209330; https://doi.org/https://doi.org/10.1093/rheumatology/kev269